Drug development targeting histamine <i>N</i>-methyltransferase

Mitochondrial Targeting for Drug Development

Histamine Receptors as Potential Therapeutic Targets for Cancer Drug Development

Although research over the last decade has led to new and improved therapies for a variety of different diseases, anticancer drug therapy continues to have undesirable outcomes, including both poor response and severe toxicity. In addition to the critical need to discover new drugs, it is important to optimize existing therapies in order to minimize adverse reactions and maximize efficacy. In t...

Drug development targeting Mycobacterium tuberculosis signaling

Effect of amodiaquine on gastric histamine methyltransferase and on histamine-stimulated gastric secretion.

1 Amodiaquine was found to be a potent inhibitor in vitro of gastric histamine methyltransferase from human and canine corpus and from pig antrum. The ID50 for the enzyme, purified from pig antrum mucosa by ultracentrifugation and chromatography on DEAE-cellulose, was 2.5 muM. 2 In six dogs with Heidenhanin pouches the maximum secretory response to histamine (40 mug/kg i.m.) was augmented by i....

Gastric mucosal histamine and histamine methyltransferase in patients with duodenal ulcer

Histamine and histamine methyltransferase (HMT) have been measured in gastric mucosa from 110 patients with duodenal ulcer and 62 control subjects. Both antral and fundic mucosa had similar levels of HMT activity despite antral mucosa containing significantly less histamine. Patients with duodenal ulcer had significantly lower levels of fundic mucosal HMT activity and lower concentrations of fu...